ALZN Company Profile and Key Details

Alzamend Neuro, Inc. has 3.80 million shares outstanding. The public float is 3.79 million shares, elevated short interest at 9.28% of float. This equals 263.39 thousand shares. The short ratio is 2.91 days. Institutional investors hold 3.97% of the float. Insiders own 2.26%. GUSTAFSON MARK holds 60.00 thousand shares, Jackman Stephan has 45.50 thousand shares and Katzoff David J has 5.54 thousand shares. Over the past six months, insider transactions show net selling. They sold 666.42 thousand shares across 19 transactions.

ALZN has shown sold momentum, gaining 3.86% over the past week and 9.01% over the past quarter, though year-to-date performance is up 32.97%. Short-term trend indicators are bullishly aligned (SMA20 6.39%, SMA50 -0.25%, SMA200 -18.35%). The stock’s 14-day RSI is 53.33 (neutral), while the ATR of 0.16 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -79.55% below its high and over 31.65% above its low. Average 10-day trading volume of 51.64 thousand shares is below the 3-month average of 74.09 thousand, indicating normal recent market interest.

Alzamend Neuro, Inc. generated EPS of -$5.50 over the past year. Five-year average earnings growth is 30.49%. The latest quarter delivered EPS of -$0.30. The next quarter is forecast at -$0.53. Next year's EPS is expected at -$17.63. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $20.00. The high target offers 1964.22% upside. The low target suggests 817.43% downside. The mean target is $37.25. This offers 1608.72% upside. Alzamend Neuro, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended December 09, 2025, missed forecasts by -63.86%. The prior quarter beat by -65.31%. Over the last six quarters, Apple has recorded several small beats. These include -47.48% in September 11, 2024.

Alzamend Neuro, Inc. (NASDAQ:ALZN) closed at $2.18 USD, gaining $0.20 (10.10%) from the previous close of $1.98. The stock is currently mid-range between its 52-week high and low $1.58 and $10.17. With a market capitalization of about $6.84 million, Alzamend Neuro, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.24). Key stats such as the average daily volume over the past year has been around 73.72 thousand shares, in line with its 52-week average. Headquartered in Atlanta, GA, Alzamend Neuro, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Stephan Jackman, the company employs approximately 4 people and listed since June 15, 2021. Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.

Alzamend Neuro, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.02. This means the shares are trading above this model’s fair value.

Alzamend Neuro, Inc. trades at a P/E ratio of -1.19, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.6 suggesting the stock is closer to book value. The P/FCF stands at -1.11, also above market averages.

Our AI price prediction model suggests that Alzamend Neuro, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.33%, with price expected at $2.03 by March 20, 2026, within a range of $1.90 to $2.18 3-Month Outlook: Projected fall of -76.67%, reaching $0.49 by June 04, 2026, with a range of $0.12 to $0.86. 1-Year Outlook: Projected loss of -99.52%, with price at $0.01 by March 05, 2027, within a range of $0.00 to $6.33.

Alzamend Neuro, Inc. (NASDAQ:ALZN) shares are up 32.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Alzamend Neuro, Inc. trading at a premium to the broader market with a P/E of -1.19. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $27.21, suggesting 1195.71% upside. Our AI forecast model points to short-term weakness (-3.33% over two weeks), a medium-term fall (-76.67% over three months), and a longer-term loss (-99.52% over one year), with expected trading ranges indicating moderate volatility.